A number of healthcare stocks fell in the afternoon session after several negative developments weighed on the sector. Weakness in managed care providers was a significant factor, with companies like Elevance Health and Humana seeing declines due to an analyst downgrade and a lost lawsuit regarding Medicare bonus payments, respectively.
Investors looking for hidden gems should keep an eye on small-cap stocks because they’re frequently overlooked by Wall Street.
Many opportunities exist in this part of the market, but it is also a high-risk, high-reward environment due to the lack of reliable analyst price targets.
A number of stocks fell in the afternoon session after the U.S. administration announced a sharp escalation in trade tensions by threatening new tariffs on Canada.
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. But financial performance has lagged recently as players offloaded surplus COVID inventories in 2023 and 2024, a headwind for overall demand.
The result? Over the past six months, the industry has tumbled by 6%. This performance is a far cry from the S&P 500’s 7.5% ascent.
A company with profits isn’t always a great investment.
Some struggle to maintain growth, face looming threats, or fail to reinvest wisely, limiting their future potential.
Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside potential.
However, it’s worth remembering that analysts rarely issue sell ratings, partly because their firms often seek other business from the same companies they cover.
Earnings results often indicate what direction a company will take in the months ahead. With Q1 behind us, let’s have a look at Solventum (NYSE:SOLV) and its peers.
The Russell 2000 (^RUT) is packed with potential breakout stocks, thanks to its focus on smaller companies with high growth potential.
However, smaller size also means these businesses often lack the resilience and financial flexibility of large-cap firms, making careful selection crucial.
As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q1. Today, we are looking at surgical equipment & consumables - diversified stocks, starting with STERIS (NYSE:STE).
Looking back on surgical equipment & consumables - diversified stocks’ Q1 earnings, we examine this quarter’s best and worst performers, including CONMED (NYSE:CNMD) and its peers.
Medical tech company CONMED (NYSE:CNMD) beat Wall Street’s revenue expectations in Q1 CY2025, with sales up 2.9% year on year to $321.3 million. The company expects the full year’s revenue to be around $1.36 billion, close to analysts’ estimates. Its non-GAAP profit of $0.95 per share was 17.1% above analysts’ consensus estimates.
Generating cash is essential for any business, but not all cash-rich companies are great investments.
Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities.
Stability is great, but low-volatility stocks may struggle to deliver market-beating returns over time as they sometimes underperform during bull markets.
Medical tech company CONMED (NYSE:CNMD) reported Q1 CY2025 results beating Wall Street’s revenue expectations, with sales up 2.9% year on year to $321.3 million. The company expects the full year’s revenue to be around $1.36 billion, close to analysts’ estimates. Its non-GAAP profit of $0.95 per share was 17.1% above analysts’ consensus estimates.
Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside potential.
However, it’s worth remembering that analysts rarely issue sell ratings, partly because their firms often seek other business from the same companies they cover.
Over the last six months, CONMED shares have sunk to $51.84, producing a disappointing 19.7% loss - worse than the S&P 500’s 7.3% drop. This was partly driven by its softer quarterly results and may have investors wondering how to approach the situation.
